Today: 1 July 2026
TSMC stock jumps 5% premarket after Goldman lifts target; earnings countdown starts
5 January 2026
1 min read

TSMC stock jumps 5% premarket after Goldman lifts target; earnings countdown starts

New York, Jan 5, 2026, 05:56 EST — Premarket

  • TSMC’s U.S.-listed shares rose more than 5% in premarket trade, tracking a record move in Taipei.
  • Goldman Sachs raised its price target on the chipmaker, flagging tight capacity and strong AI-driven demand.
  • Investors now look to TSMC’s December sales update on Jan. 9 and quarterly results on Jan. 15.

Shares of Taiwan Semiconductor Manufacturing Co. (TSMC) climbed 5.2% to $319.61 in U.S. premarket trading on Monday, after the chipmaker’s Taipei-listed stock hit a fresh record on a Goldman Sachs target hike.

The move matters because TSMC is the world’s largest contract chipmaker — a “foundry” that manufactures chips designed by others — and its order book is treated as a read-through on global demand for high-end processors used in data centres. Asia’s tech-heavy markets have started 2026 with renewed momentum as investors position for another year of heavy spending on artificial intelligence infrastructure. Reuters

Investors also have near-term catalysts in view. TSMC’s investor relations calendar shows a December 2025 monthly sales update due on Jan. 9, followed by its fourth-quarter 2025 earnings conference on Jan. 15.

Goldman lifted its target price on TSMC to NT$2,330 from NT$1,720 and reiterated a “conviction buy” rating, an Investing.com report said. The report said the bank expects fast growth in AI-related computing to keep “silicon demand” — demand for chips — ahead of supply well into 2027. Investing

Goldman Sachs analyst Bruce Lu called AI a “multi-year growth engine,” according to TipRanks, as he raised his target and lifted earnings estimates. TipRanks

Goldman also expects TSMC to spend more than $150 billion in capital expenditure from 2026 to 2028 to add capacity, while forecasting continued tightness in 3-nanometre and 5-nanometre “wafer” capacity — the silicon discs chips are built on — through 2026 and 2027, Investing.com said. Investing

In Taipei, TSMC shares jumped as much as 7% to a record NT$1,695 and extended a run of record highs over the past two sessions, the same report said.

Separately, Taiwanese prosecutors said they had filed additional charges against the Taiwan unit of Tokyo Electron and others over alleged theft of TSMC trade secrets, expanding a case that first surfaced last year. Tokyo Electron said its parent company had not been indicted and the situation did not affect its financial results.

The risk for bulls is that expectations run ahead of what TSMC can deliver in its next guidance update, particularly on pricing, capacity expansion and margins as it ramps overseas production. Any shift in the pace of AI infrastructure spending or new trade friction affecting chip supply chains could also test sentiment.

The next hard markers are TSMC’s December monthly sales release on Jan. 9 and its Jan. 15 earnings conference, when investors will parse its 2026 outlook for revenue growth, capital spending and capacity constraints.

Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation.

Stock Market Today

  • Tandem Diabetes (TNDM) Slides as Founder’s Modular Medical Launches Insulin Patch Pump
    June 30, 2026, 8:44 PM EDT. Tandem Diabetes Care (NASDAQ:TNDM) shares fell 2.5% after Modular Medical-run by Tandem's original founder Paul DiPerna-said it has started patient use for its Pivot tubeless insulin patch pump. The launch pushes Modular into a crowded field and targets insulin users who still rely on daily injections, raising worries about fresh competition. Tandem later clawed back some of the loss, finishing at $15.43. The stock is down 28.4% in 2024 and still trades well off its 52-week peak, down 45.4%. Analysts have ticked the name higher recently, pointing to better pharmacy channel trends and signs of sales recovery. The market is taking the new threat seriously, but not seeing it as a game-changer yet.
Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Previous Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus
Next Story

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus

Go toTop